Trials / Terminated
TerminatedNCT00055198
Daptomycin for the Treatment of Infections Due to Gram-Positive Bacteria
A Compassionate Use Protocol for Intravenous Daptomycin for the Treatment of Infections Due to Gram-Positive Bacteria That Cannot be Adequately Treated With Currently Available Therapy
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 75 (planned)
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to provide daptomycin, an antibiotic, to patients who are failing conventional therapy, or who cannot take approved antibiotics for one reason or another.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | daptomycin |
Timeline
- Start date
- 2002-12-19
- Primary completion
- 2004-01-26
- Completion
- 2004-01-26
- First posted
- 2003-02-21
- Last updated
- 2017-06-14
Source: ClinicalTrials.gov record NCT00055198. Inclusion in this directory is not an endorsement.